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Abstract
Proinflammatory cytokine TNFα plays critical roles in promoting malignant cell
proliferation, angiogenesis, and tumor metastasis in many cancers. However, the
mechanism of TNFα-mediated tumor development remains unclear. Here, we show
that IKKα, an important downstream kinase of TNFα, interacts with and
phosphorylates FOXA2 at S107/S111, thereby suppressing FOXA2 transactivation
activity and leading to decreased NUMB expression, and further activates the
downstream NOTCH pathway and promotes cell proliferation and tumorigenesis.
Moreover, we found that levels of IKKa, pFOXA2 (S107/ 111), and activated
NOTCH1 were significantly higher in hepatocellular carcinoma tumors than in normal
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liver tissues and that pFOXA2 (S107/111) expression was positively correlated with
IKKα and activated NOTCH1 expression in tumor tissues. Therefore, dysregulation of
NUMB-mediated suppression of NOTCH1 by TNFα/IKKα-associated FOXA2
inhibition likely contributes to inflammationmediated cancer pathogenesis. Here, we
report

a

TNFα/IKKα/FOXA2/NUMB/NOTCH1

pathway

that

is

critical

for

inflammation-mediated tumorigenesis and may provide a target for clinical
intervention in human cancer.
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CHAPTER 1 INTRODUCTION

1.1 Liver cancer and inflammation

Liver cancer is the third most common cancer in the world1. 90% liver cancer
patients die within a year after diagnosis, and 5-year survival rate of liver cancer is
only 6.9%2,3. In 2008, it was estimated that there were about 700,000 new cases of
liver cancer worldwide, and a similar number of patients died as a result of this
disease4-6. Nativity, residential enclave status, and neighborhood SES characterize
Hispanics and Asians with significantly unequal incidence rates of liver cancer,
implicating behavioral or environmental risk factors, including primarily associated
with geography incidence rate risk factor chronic hepatitis B virus (HBV) and
hepatitis C virus (HCV) infections, dietary aflatoxin exposure, alcohol-related
cirrhosis, fatty liver disease, obesity, smoking, diabetes, and iron overload7,8.

It is not a surprise to see the tight correlation between liver inflammation and
liver cancer. Back to early 1863, the founder of modern pathology, Dr. Rudolf
Virchow suggested that “lymphoreticular infiltrate” reflected the origin of cancer at
sites of chronic irritation9,10. It is the first time that people noticed the association
between inflammation and cancer. Since then, the relationship between
inflammation and cancer has been observed and studied for a long time. Now, the
causal relationship between inflammation and cancer is more widely accepted with
general molecular and cellular mechanisms underneath. One of typical examples is
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extrinsic factors induced inflammatory or infectious conditions augment the risk of
developing cancer at certain anatomical sites (for example, the liver)11-13. This
extrinsic pathways converge resulting in the activation of transcription factors, like
nuclear factor-κB (NF-κB), signal transducer and activator of transcription 3
(STAT3) and hypoxia-inducible factor 1α (HIF1α), in tumour cells. These
transcription factors coordinate the production of inflammatory mediators, including
cytokines and chemokines. The proinflammtory cytokines and chemokines, such
as tumor necrosis factorα (TNFα), multiple interleukin factors recruit and activate
various leukocytes, most notably cells of the myelomonocytic lineage. The
cytokines activate the same key transcription factors in inflammatory cells, stromal
cells and tumour cells, resulting in more inflammatory mediators being produced
and a cancer-related inflammatory microenvironment to enhance cell proliferation,
cell survival, cell migration and tumor angiogenesis, thereby promoting tumor
development14-16. However, the mechanism of how specific type of inflammation
targets unique cancer markers to promote tumorigenesis in different tumor
development stages is still obscure. Therefore, uncovering the mechanism
involving in inflammation-cancer process for further therapeutic and prevention
study is urgently needed, and the identification of the molecules associated with
inflammation-mediated tumorigenesis will provide a novel strategy for development
anticancer or prevention agents.

2

1.2 TNFα pathway and cancer

The microenvironment surrounding tumors comprise with couple distinct
types of cells, including fibroblasts, endothelial cells, and inflammatory cells. And a
neoplastic clonal cell population exists in stromal and infiltrating inflammatory cells
to provide sustenance and facilitate the potential metastatic process of the
malignant cell 17,18. One of the crucial aspects of the tumor micro-environment is the
cytokine-mediated communication between the tumour and stromal cells19. Tumor
necrosis factor-α (TNF-α), as one of most important inflammatory factor, have large
amount

of

activities

to

permit

cell-cell

communication

and

involve

in

inflammation-associated tumorigenesis 20.
The classical signaling pathway responded to TNFα is NF-κB pathway via
TNFR1. TNFR1 engagement leads to recruitment of the adaptor molecule TRADD,
which subsequently recruits the signaling proteins TRAF2 and RIP1. TRAF2
mediates recruitment of the IKK complex.TAB2 and TAB3 interact with TRAF2 and
TAK1 resulting in the activation of TAK1. TAK1-phosphorylated IKKβ is on its
activation loop. Active IKK phosphorylates IκBs on conserved serines, triggering
their degradation through β-TRCP ubiquitin-proteasome proteolytic system and
release of bound NF-κB dimers, which translocate to the nucleus to drive gene
transcription which associates with tumorigenesis 21.
Accumulated evidences show that he low-dose, chronic TNFα production is a
feature of many tumor cells22. For example, the tumor-promoting role of TNFα was
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similarly investigated in models of hepatic carcinogenesis. TNFRI-/- mice displayed
reduced oval cell (hepatic stem cell) proliferation during the pre-neoplastic phase of
liver carcinogenesis, correlating with fewer tumours than wild-type mice23. In
addition, dysregulation of TNFα-IKK-NF-κB pathway is usually found in many human
cancers. In Barrett’s esophageal adenocarcinoma and hepatoma, TNFα-IKK-NF-κB
pathway is upregulated24,25; Mutation of CYLD induced constitutive activation of NF-κB
occurs in cylindromatosis patients26-28; couple of mutations or loss-fuction IκB are
dected in couple of cancer types, including colon cacner and breast cancer29-33. These
pathological findings indicate the clinical relevance of TNFα signaling pathway in
human cancer development.

1.3 Independent Role of IKK subunits to NF-κB pathway

IKKα and IKKβ are major downstream serine/threonine kinases which have
multiple functions dependent and independent on the NF-κB pathway. Previous
study show that NF-κB-independent activities induced by TNFα34-40, For example,
independent IKKβ positively regulate inflammation linked tumorgenesis and
angiogenesis in several cancer types41-43.
It has also been reported that IKKα can be activated by TNFα treatment
independently of IKKβ. For example, two Nature papers, published side-by-side,
showed that IKKα, in response to TNFα, translocates from the cytoplasm to the
nucleus and phosphorylates histone H3 to regulate transcription of target genes44,45.
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In addition to histone H3, we also reported that IKKα is able to phosphorylate CBP
and switches CBP binding preference from p53 to NF-κB upon TNFα stimulation 46.
These TNFα-induced IKKα activities are independent of IKKβ. There are several
reports that strongly support the idea that IKKα is able to contribute to tumor
development independently of NF-κB. For instance, the nuclear function of IKKα
has also been implicated in prostate cancer metastasis by inhibiting the expression
of the tumor suppressor, Maspin, in mouse model47. Moreover, IKKα is able to
phosphorylate and regulate ER, AIB1, CYCLIN D1, and β-CATENIN in cell
proliferation48-52.

Briefly,

IKKα

can

increase

cyclin

D1

expression

by

phosphorylating and activating the estrogen receptor-α and SRC-3 on the cyclinD1
promoter as well as phosphorylate cyclinD1 directly as a feedback loop. These
activities contribute to oncogenic effects. These findings suggest that IKKα has the
unique ability in regulating versatile physiological and pathological functions, which
are independent of NF-κB.

1.4 Forkhead Box Protein (Fox) and Cancer

Fox proteins are super transcriptional regulator family that is evolutionarily
conserved. This family defined by a unique DNA-binding domain (DBD) called the
forkhead box or winged helix domain53,54. Members of this family bind DNA as
monomers and regulate downstream target gene expression. The N terminus and
C terminus contain transactivation domains whose function is regulated at the level
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of phosphorylation55. So far, there are 17 Fox gene subfamilies, with at least 41
genes identified in humans56,57. Fox proteins play important roles in a wide
spectrum of biological processes, including metabolism, development, migration
and cell cycle events58-62. Since Fox proteins control these essential homeostatic
processes, the fact that losing or gaining of their functions alter cell fate and lead to
tumorigenesis is in expectation. For example, in FoxA family, which shows a
unique tissue-specific expression pattern, FoxA1 is essential for differentiation of
epithelial cells in normal prostate, while prostate of FOXA1 knockout mice show
hyperplastic lesions63,64; Overexpressed FoxA2 act as a key regulator in colon liver
metastasis65. Except FoxA, several Fox subfamilies, such as FoxO, FoxP and
FoxM are verified to link to tumorigenesis and the progression of certain
cancers66-70.
Post translational modification, such as phosphorylation, acetylation and
ubiquitination regulate Fox proteins activities. One of most clear example is
FoxO3A. Several upstream kinases including Akt, JNK, CDK2 and IκB kinase (IKK)
phosphorylate FoxO3A to induce its nuclear export and degradation. Deregulation
of these kinases normally happen in tumors and contribute to tumorgenesis71-74.
For example, disruption of IKK affects chromatin remodeling and NFκB signaling.
Moreover, IKK has been shown to physically bind to and phosphorylate FoxO3A in
tumor, and cytoplasmic FoxO3A correlates with the expression of IKKβ in many
tumors and associates with poor prognosis in breast cancer72. Recent studies also
show that insulin-induced FoxA2 phosphorylation by Akt promotes FoxA2 nuclear
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exclusion, inactivates downstream target genes and unrestrains hepatic
gluconeogenesis in type 2 diabetes, a disease strongly associated with cancers.
Not only phosphorylation, acetylation and mono-ubiquitylation of Fox proteins play
critical part in Fox regulated cancers. For example, FoxP3 suppresses of target
gene expression involving a histone acetyltransferase–deacetylase complex75,76.
Deregulation of Fox factors can promote tumorigenesis by favoring
proliferation and survival through the repression or induction of gene expression.
For example, FoxO3a regulate FasL and p27 transcription77,78, FoxA2 is a well
known regulator of GATA3 gene.79,80 The advent of chromatin immunoprecipitation
coupled with microarray technology (ChIP-chip) brings larger scale of views of Fox
transcriptional regulatory functions than which on traditional gene-to-gene basis81-85.
Recently,

genome-wide

ChIP-sequencing

experiments,

which

can

detect

transcription factor binding in any genomic region accurately, are used in FoxA2 to
screen its downstream target genes in adult mouse liver. A large number of novel
Foxa2 binding targets are reported for the first time, including both tumor suppress
genes and well known oncogenes, such as fgf1, numb, and dlk186,87.
Based on our so far knowledge of Fox family, therapies that indirectly target
Fox factors through cofactors or repressors of Fox, or direct target Fox by
modifying the post-translational regulation of Fox factors, may enable a shift in
Fox-induced gene expression, and change aberrantly regulated Fox proteins
functions. Based on cooperativity with other regulatory factors, redundancy and
tissue-specific roles of Fox proteins, Fox family proteins targeted drugs are
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promising to have lower toxicity and higher tissue specificity. In clinical, some Fox
family proteins are used, or have potential to be used, as both indirect and direct
targets88. Breast carcinoma chemotherapeutic drugs pacliaxel activates JNK, which
modulate the stability of FoxO3A by phosphorylation DBD of FoxO3A so that
blocks tumorgenetic cascades regulated by FoxO3A89,90. FoxA1 as a marker for
luminal subtype A breast cancer is also a good therapeutic candidate91. (Fig1)

Fig 1 FOX proteins work as therapeutic targets in clinic.FOXM1 are used in HCC
and Osteosarcoma; FOXO3A are used in both breast cancer and melanoma;
FOXP3 are also used in melanoma via vaccination.

1.5 NOTCH pathway and its role in cancer

The discovery of a notch on wings of Drosophila melanogaster in 1914 is the
first time NOTCH gene get noticed

92

. With later one century studies, researchers
8

are opening the door to an ever-widening understanding of Notch family and
related signalings which controlled multiple cellular processes, influence cell fate
decision.
The Mammalian Notch family has four members, NOTCH1, NOTCH2,
NOTCH3 and NOTCH4

93

. The map of NOTCH signaling is not fully clear, but the

general scheme is accepted. NOTCH signaling is initiated by the binding of
NOTCH ligands with NOTCH receptors. After S1 cleavage of NOTCH precursor,
mature NOTCH which comprises with two subunits, ECD (extracellular domain)
and ICD (intracellular domain), changes its conformation, leading to S2 cleavage
site exposure. S3 cleavage mediating by γ-secretase complex follows with S2
cleavage consequently. The S3 cleavage results in the release of NICD from cell
plasma membrane and translocation of NICD to nucleus. Major function of nuclear
NICD is to mediate the conversion of the CBF1–Su(H)–LAG1 (CSL) repressor
complex

into

a

transcriptional

activation

complex,

therefore

initiates

a

transcriptional cascade to activate or repress target genes, including p21, Myc and
HES and HEY family94-96.

The first role of NOTCH found in human cancer is to be an oncogene in
T-ALL. Most of T-ALL cases have activating mutation of Notch1, which leads to
constitutive activating of Notch pathway to promote tumorigenesis97. Comparing to
causative role of Notch in T-ALL, the role of Notch signaling in solid tumors is
vague. The status of The Notch signaling is highly dependent on the spatial and
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temporal context of Notch activation and the status of other signaling pathways in
the cells as well98.

Several processes, including proteolysis, glycosylation, ubiquitylation and
phosphorylation99, control Notch activation. Ligands overexpression, abnormally
activated receptors or dysregulation of negative regulators may lead to aberrant
activation of the Notch pathway100 Some of these circumstance are deregulated in
cancers, resulting in aberrant Notch signaling101-103.
NUMB and NUMB-like proteins function as signalling inhibitors for Notch by
targeting the membrane-bound Notch for degradation following activation104. Loss
of NUMB has been detected in over 50% percent of breast carcinoma105, and
possibly results in the stabilization and hyperactivation of Notch. In addition,
NUMB binds to p53 and MDM2 to prevent ubiquitylation of p53106. Thus, loss of
NUMB in a large proportion of breast cancers can result in increased Notch activity
and loss of p53 tumor suppressor function, resulting in an aggressive tumor
phenotype with poor prognosis.
In contrast to its oncogenic actitives in multiple cancer types, Notch has been
proved as a tumor suppressor in come cancer types as well. This tumor suppressor
activities is worked as a result of crosstalk with other signaling pathways, which
decrease cell proliferation, increase apoptosis or cellular differentiation107. For
example, NOTCH could block WNT signaling to suppress tumorgenesis thereby
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driving cells toward a more differentiated phenotype108 .

The knowledge of the extensive crosstalk of the Notch pathway with other
pathways such as the epidermal growth factor receptor (EGFR) pathway, WNT
pathways, could prove useful in developing combinatorial cancer therapies109.

1.6 Statement of problem, hypotheses and project goals

HCC is a typical tumor on a background of inflammation mainly triggered by
exposure to infectious agents (hepatotropic viruses, inflammatory cytokines). In the
past twenty years, many studies unfold significant alterations of different cytokines
and their cascades in liver cirrhosis and HCC. However, the molecular links
between inflammation and cancer progression are still remaining contradiction and
not completely known.
In previous studies, TNFα tumor promoting effects were found in several
genetic mouse model of inflammation-related carcinogenesis through activating the
key inflammatory transcriptional regulator NF-κB. Contrarily, hepatocyte-specific
deletion of IKKβ gene or ablation of IKKγ/NEMO leads to the spontaneous
development of HCC110-113. These phenomena indicate that other cascades, other
than traditional NF-κB, are involved in TNFα induced liver cancer. Based on our
previous research that IKKα/IKKβ can independently regulate downstream
cascades to lead tumorgenesis and angiogenesis by phosphorylating Fox family,
an interesting question is rising, whether IKKα/IKKβ dependent Fox cascades play
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critical role in inflammation-induced liver cancer? If yes, which Fox is the player?
In addition, in search of mechanisms that may be involved in TNFα-mediated
tumorgenesis, the previous study showed that controversial roles of NF-κB in
TNFα-mediated liver cancer in several genetic mouse models, thus it is still not
clear whether IKKα/β has a role independent to NF-κB in the TNFα-mediated
tumorgenesis. Preliminary data showing that in HCC patients, p-IKK expression
has positive correlation to activated NOTCH1 expression. Therefore, it is possible
that there are other NF-κB-independent pathways involved in TNFα-mediated NOTCH1
production and tumorigenesis. We hypothesize that TNFα induces NOTCH1 activation
through IKK-mediated phosphorylation of FOX protein, therefore increase of NOTCH1
pathway activation, finally leading to tumorigenesis.

CHAPTER 2 MATERIALS AND METHODS
2.1 Cell culture
Human hepatocellular carcinoma cancer cell lines (Hep3B, Huh-7, and HepG2),
human embryonic kidney cell lines (HEK-293 and HEK-293T) and mouse
embryonic firbroblasts (Ikkα-/-, Ikkβ-/-) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM)/F12 medium supplemented with 10% fetal bovine serum. For
transient transfection, cells were transfected with DNA by either Lipofectamine with
Plus reagent or electroporation.
2.2 Plasmids, antibodies, and chemicals
We constructed Myc-FOXA2- and GFP-FOXA2-expressing plasmids by
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inserting hFOXA2 complementary DNA (cDNA) into pcDNA6 and pCMV-EGFP
vectors containing the Myc and GFP tags, respectively. We generated the
GST-FOXA2-expressing plasmid by subcloning the FOXA2 fragment into the
pGEX-6P-1 GST vector. Different mutant forms of the FOXA2 construct were
generated by subcloning the FOXA2 fragment into pcDNA6 and pCMV-EGFP
vectors. Mutants were generated using the QuikChange Multi Site-Directed
Mutagenesis Kit (Stratagene). The FOXA2 and mutant expression plasmids were
constructed into retroviral pBABE-Puro and pBABE-GFP vectors for retroviral
infection and expression.
Antibodies against FLAG (F3165, Sigma), Myc (11667203001, Roche),
IKKα (sc-7606, Santa Cruz), IKKβ (sc-8014, Santa Cruz), IκBα (9242S, Cell
Signaling Technology), TNFα (Santa Cruz Biotechnology, SC-8301), IκBα (Santa
Cruz Biotechnology, SC-371), IKKγ (Santa Cruz Biotechnology, SC-8330), RHEB
(Santa Cruz Biotechnology, SC-6341), GAPDH (Santa Cruz Biotechnology,
SC-20357),

NOTCH1

(NICD)

(sc-32745,

Santa

Cruz

Biotechnology),

pIκBα(S32/S36) (Cell Signaling Technology, 9246),NUMB (ab14140, Abcam),
FOXA2 (ab60721, Abcam), p-IKKα(S176/180) (2697, Cell Signaling), α-tubulin
(T-5168, Sigma), and actin (A2066, Sigma) were purchased from the indicated
suppliers. Antibodies to the S107/111 phosphorylation sites of FOXA2 were
generated at China Medical University. Synthetic phosphorylated peptides
representing portions of FOXA2 around both S107 and S111 were used as
antigens for producing antibodies.
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TNFα was purchased from Sigma, and Bay (43-9006) and SCI34 were
purchased from CalBiochem. Full-length recombinant GST-IKKα and His-IKKβ
proteins were purchased from EMD Millipore. The liver tumor tissue array was
purchased from US Biomax.

2.3 siRNA
Hep3B cells or Huh-7 cells were transfected with IKKα ON-TARGETplus siRNAs
(LQ-003473-00-0002), NUMB ON-TARGETplus siRNAs (LQ-015902-00-0002),
NOTCH ON-TARGETplus siRNAs (LU-007771-00-0002), or control SMARTpool
siRNA (Upstate Biotechnology, D-001206-13-05) by lipofectamine with plus reagent
and lysed 72 h after transfection.

2.4 Transfection
For transient transfection, cells were transfected with DNA by either SN
liposome (59), lipofectamine with plus reagent, or electroporation using a Nucleofector
1 device (Amaxa) with electroporation buffer (137 mM NaCl, 5 mM KCl, 0.7 mM
Na2HPO4, 6 mM glucose, and 20 mM HEPES, pH 7.0). To investigate the effects of IKK
on p-FOXA2 (Ser107/111), or NOTCH1 activation, the transfected cells were
serum-starved overnight and extracted directly or after stimulation with TNFα (20ngl/ml),
for 30 min or 24h.
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2.5 In vitro pull-down assay
Recombinant IKKα proteins and IKKβ proteins (EMD Millipore 21233; Upstate
Biotechnology, 14-485) were incubated with in vitro transcription and translation lysates
of myc-tagged TSC1, which was produced using a TNT coupled reticulocyte lysate
system (Promega), in binding buffer (25 mM Tris-HCl, pH 7.5, 125 mM NaCl, 1 mM
phenylmethylsulfonyl fluoride, 1 µg of leupeptin/ml, 1 µg of aprotinin/ml, and 1 µg of
pepstatin/ml) for 1 h at 4°C. Rabbit IgG antibody (rIgG) or anti-IKKβ antibody was then
added

and

incubation

was

continued

at

4°C

overnight.

The

resulting

immunocomplexes were precipitated with protein A-Sepharose beads (Roche) at
4°C for 4 h and washed extensively with Tris-buffered saline, and the bound
proteins

were

eluted

with

sodium

dodecyl

sulfate-polyacrylamide

gel

electrophoresis sample buffer and then analyzed by Western blotting.

2.6 Immunoprecipitation and immunoblotting
Cells were lysed in RIPA-B buffer (20 mM Na2HPO4 [pH 7.4], 150 mM NaCl ,
1% Triton X-100) with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 5
mM NaF, 2 mM sodium orthovanadate, 3µg/ml aprotinin, and 750µg/ml
benzamidine). For immunoprecipitation, the samples were precleaned with either
protein A or protein G agarose for 1 hr at 4 oC. Precleaned cell lysates were
Proteins were immunoprecipitated by indicated antibodies for overnight at 4 oC,
incubated with either protein A or protein G agarose for 3 hr at 4 oC, washed
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ice-cold RIPA-buffer with protease inhibitors four times, resolved by SDS-PAGE,
and transfer to PVDF membranes. For immunoblotting, membranes were blocked
with TBST buffer (10 mM Tris-HCl (pH 7.9), 150 mM NaCl, and 0.05% Tween 20)
with either 5% BSA or 5% skim milk, incubated with indicated primary antibodies,
subsequently incubated with HRP-conjugated secondary antibodies and detected
by ECL (Amersham Biosciences).

2.7 In vitro kinase assays
Briefly, 80% confluent Hep3B cells were serum starved for 16 h and then
treated with/ or without 20ng/ml TNFα for 30 min. The cells were lysed and
immunoprecipitated with

either anti-IKKα antibodies and analyzed by in vitro

kinase assay using the purified GST-FOXA2 as substrates, respectively, and
incubate at 30°C for 30 min in the presence of 50 mM ATP in a kinase buffer with
5 µCi [ -32P]ATP. Reaction products were subjected to SDS-PAGE and analyzed by
autoradiography.

2.8 Identification of in vivo phosphorylation sites by mass spectrometry
After protein gel electrophoresis, bands corresponding to FOXA2
phosphorylated by IKKα in vivo were identified, excised from gels, and subjected to
tryptic digestion. After being isolated by immobilized metal affinity chromatography,
the

enriched

phosphopeptides

were

chromatography/tandem mass spectrometry.
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analyzed

by

micro-liquid

2.9 Real-Time PCR
Primer sequences used to quantify real-time PCR were as follows: Hey2:
5′-AAACAAGGATCTGCAA-3′ and 5′-CGGAATCCTATGCTCATGAA-3′; Hey1:
5′-TATCTGAGCATCATTGAA-3′ and 5′-TGTGCGGGTGATGTCCGAA-3′; p21:
5′-GTGAAGGCTGTGTCTTC-3′
5′-AATTTCGATTTTCA-3′

and

and

5′-TACAGATTTTGTGTGCTCT-3′;

5′-CTTGCAGGCACCTTTGGGGG-3′;

p27:
Hes6:

5′-ATCAACGAGAGCCTG-3′ and 5′-CACTGGATGTAGCCGGCAGCGAA-3′.

2.10 ChIP and Re-ChIP Assay
Primer

sequences

used

for

ChIP-PCR

5′-AATGAAATTGGATGCATTGAGACCA-3′

were

as

follows:

(forward)

NUMB:
and

5′-AAGCTTATCTCTGCTAGCTTTATTCA-3′ (reverse). GAPDH promoter was used
as a negative control.

2.11 Anchorage-Independent Growth Assay
Briefly, the cell-growth matrix consisted of base agar and top agarose in six-well
culture plates. The base layer (1.5 ml) contained DMEM/F12 medium, 10% FBS,
and 0.5% agar. The top layer (1.5 ml) contained DMEM/F12 medium, 10% FBS,
0.35% agarose, and the suspension of cells (5 × 103). The foci were counted after 3
weeks. The modifications used for retrovirus-infected Hep3B cells are as follows:
retrovirus-infected cells (5 × 104) were mixed with 0.5% agarose and poured onto a
bed of 1% agar. Both the top and the bottom layers were prepared in DMEM/F12
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medium with 10% FBS.

2.12 Immunohistochemical Staining
Briefly, human histoarrays of multiple cancerous tissues and human liver
cancer tissues primary tumor specimens of HCC, colon, lung, and prostate cancer
(IMH-365, US Biomax) were incubated with antibodies directed against p-IKKα or
NICD (activated NOTCH1), detected with biotin-conjugated secondary antibody
and avidin–peroxidase, and visualized by aminoethylcarbazole chromogen.
Images were analyzed by ACIS (Dako). The samples were divided into two groups
according to staining intensity: low (+/−) and high (+/+).The human liver primary
tumor samples for Western blotting were received from Gaoxiong Medical Shool..
Fisher’s exact test and Spearman rank correlation were used for statistical analysis; P
< 0.05 was considered statistically significant. According to histologic scoring, the
intensity of staining was ranked into four groups: high (score 3), medium (score 2), low
(score 1), and negative (score 0). The immunoreactivities for pIKK, NOTCH1 were
semiquantitatively scored using a well-established immunoreactivity score system in
which immunoreactivity score was generated by incorporating both the percentage of
positive tumor cells and the intensity of staining.

2.13 Mouse Model for Tumorigenesis
We performed the tumorigenesis assay for retrovirus-infected cells with both
a liver cancer subcutaneous mouse model and an orthotopic mouse model, which
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has been described elsewhere. Cells were injected subcutaneously. After tumors
reached 2–3 mm in diameter, tumors were harvested, dissected into small pieces
(1*1*1 mm3), and transplanted into the livers of new mice (n = 5 per group). TV was
calculated according to the formula described by Yaguchi et al.: TV = 0.5 3 length *
width2. Animal experiment protocol number is approved by by the UT MD Anderson
Cancer Institutional Animal Care and Use Committee under protocol number ACUF
06-87-06139. Thirty patient samples are from National Cheng-Kung University
Hospital. Thirty patients admitted to National Cheng-Kung University Hospital with
HCC who received curative surgery between January 1, 2003, and December 31,
2006, were enrolled, and National Cheng-Kung University Hospital Institutional
Review Board approved the protocol.

2.14 Statistical Analyses
Statistical analyses were performed with Student’s t test, Spearman’s rank
correlation test, or Pearson’s chi-square test as indicated. p < 0.05 was considered
statistically significant. R2 > 0.5 was considered statistically correlated.
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CHAPTER 3
Phosphorylated IKK expression positively correlates with activated NOTCH1
expression and high HCC tumor grade
It is well known that both TNFα triggered signal pathways and NOTCH1 signling
are critical to tumor cell proliferation and tumorigenesis in different cancer types.
However, the critical underneath molecular mechanism linking these two pathways
in

hepatocellular

carcinoma

(HCC),

especially

inflammation

associated

hepatocellular carcinoma is not clear. To address a potential crosstalk between
these two pathways in inflammation-associated HCC tumorigenesis, we examined
the expression level of p-IKK, which is an important downstream kinase of TNFα,
and the level of intracellular domain of NOTCH1, which is considered as activated
NOTCH1 in 100 human primary HCC tumor specimens by immunohistochemical
(IHC) staining. In 100 specimens, 47 of them were detected with high p-IKK
expression, and 27 of which showed high NICD expression, indicating a significant
positive correlation between p-IKK and NICD (p = 0.003, Figures 2A and 2B). In
addition, both p-IKK and NICD had higher expression levels in higher-grade tumors
(Figures 3A and 3B). To determine whether this relationship holds in other cancers,
we examined human primary tumor specimens of colon, lung, and prostate cancer
by IHC staining. Similar to our finding in liver tumors, we also found a positive
correlation between p-IKK and NICD (see Figure 4)
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Fig 2. Clinic Correlation between p-IKK and NICD
(A) Correlation between levels of p-IKKα/β and activated NOTCH1 (NICD) in 100
human primary HCC tumor specimens stained with antibodies specific to NICD and
p-IKK (P = 0.003, Pearson’s chi-square test).
(B) Two representative specimens from (A); arrows point to p-IKK and NICD.
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Fig 3 Clinic correlation between p-IKK/NICD and tumor grade
(A) Correlation between tumor grade and p-IKK expression. High p-IKK expression
correlated significantly with higher tumor grade (P = 0.035, Pearson’s chi-square
test).
(B) Correlation between expression of p-IKK, NICD and tumor grade. High NICD
expression correlated significantly with higher tumor grade (P = 0.01, Pearson’s
chi-square test).
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Fig 4 Clinic correlation between p-IKK and NICD in multiple cancer types
Association between levels of p-IKKα/β (p-IKK) and activated NOTCH1 (NICD) in
human primary tumor specimens of colon, lung, and prostate cancer stained with
antibodies specific to NICD and p-IKK (P = 0.024, Pearson’s chi-square test).

NOTCH
Total

Tumor tissues of
multiple cancer types
p-IKK

Low
(+/-)

High
(+/+)

Low

11

3

14

High

6

10

16

17

13

30

Total

P=0.024

23

CHAPTER 4 IKKα is required for TNFα-induced NOTCH1 activation
The clinical positive correlations between p-IKK and NICD raise a question in
our mind: whether TNFα/IKK might upregulate NICD expression. To validate the
relationship between IKK and NICD expression, we detected NOTCH1 intracellular
domain, which is an activated form of NICD in mouse embryonic fibroblasts (MEFs)
treating with TNFα (Figure 5). We found that after TNFα treatment, NICD
expression in MEFs increase (Figure 5, top), which indicates that NOTCH1
activation was increased upon TNF stimulation. To further investigate which
components of IKK complex regulates NICD expression, wild-type (WT), IKKα–/–,
and IKKβ–/– MEFs were treated with TNFα and compared their NICD expression
level by westernblotting assay. The NICD level in IKKα–/– MEFs was substantially
lower than in WT MEFs (Figure 5, bottom; compare lanes 1 and 2). Re-expression
of IKKα in the IKKα–/– MEFs rescued NICD expression (Figure 8, bottom; compare
lanes 2 and 3). However, re-expression of IKKβ could not affect the NICD level in
IKKβ–/– MEFs (Figure 5, bottom; compare lane 1 with lanes 4 and 5). Together,
these results indicate that IKKα, but not IKKβ, is necessary components in
TNFα-induced NICD expression, suggesting that TNFα may stimulate NOTCH1
activation through an IKKα-dependent pathway.
To further confirm that IKKα is required for TNFα-mediated increase of NICD
expression, a RBP-Jk reporter luciferase assay, which could monitor the activity of
NOTCH1 signal transduction pathways in cultured cells by showing activities of two
NOTCH1 downstream enzymes, was used as a tool to detect NOTCH1 activity.
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IKKα expression was detected by western blot analysis to make sure IKKα was
knocked down by siRNA (Figure 6, top). RBP-Jk reporter luciferase assay showed
the similar results that NOTCH1 is activated by TNFα stimulation and such
activation was that blocked by knocking down IKKα (Figure 6).

25

Fig 5 IKKα is required for TNFα-induced NOTCH1 activation
Top: WT MEFs were treated with or without TNFα (20 ng/ml) for 24 h, and cell
lysates were subjected to western blot analysis for NICD expression.
Bottom: IKKα and IKKβ were transfected into IKKα–/– MEFs and IKKβ–/– MEFs,
respectively. After treatment with TNFα (20 ng/ml) for 24 h, cell lysates were
subjected to western blotting. Lysates from MEFs without TNFα treatment served
as control. α-Tubulin was used as loading control.
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Fig 6 NOTCH1 activity was blocked by IKKα knocking down
RBP-Jk Luc and IKKα siRNA were transfected into Hep3B cells for 48 h. After
transfection, WT and IKKα-knockdown Hep3B cells were treated with TNFα for 24
h. Cell lysates were subjected to western blotting and luciferase reporter assay.
Cells were transfected with nontargeting siRNA as control. Error bars represent SD
(n = 3). * indicates, P < 0.05.
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CHAPTER 5 NUMB suppression involves in TNFα induced NOTCH1
activation

After we know TNFα/IKKα regulates NOTCH1 activation, we are trying to
know how what is the regulator in TNFα/IKKα induced NOTCH1 activation. As
NUMB

is

known

to

atagonist

NOTCH1

activation

through

degradation

membrane-bounded NOTCH1 intracellular domain, we first tested whether NUMB
expression level changed in the process of TNFα/IKKα-mediated NOTCH1
activation. We found that TNFα treatment upregulated NICD expression and at the
same time, NUMB expression level decreased in both Huh-7 and Hep3B in HCC
cell lines (Figure 7A). Consistent with our results that only IKKα, but not IKKβ,
involves in TNFα/IKKα regulates NOTCH1 activation, ectopic expression of IKKα
but not IKKβ increased NICD expression and diminished NUMB expression as well
(Figure 7B). In addition, blocking IKKα expression by siRNA knocking down
recovered TNFα-mediated NUMB downregulation and subsequent impaired
TNFα-mediated NOTCH1 activation (Figure 8A, compare lanes 2 and 4).
Knockdown of both IKKα and NUMB restored NICD expression (Figure 8A,
compare lanes 4 and 6), suggesting that TNFα/IKKα-mediated NOTCH1 activation
involves NUMB downregulation. MEFs and IKKα–/– MEFs were used to further
analyzed the relationships of IKKα, NUMB, and NICD. Higher NUMB expression
and consistently lower NICD expression were found in IKKα–/– MEFs than in WT
MEFs (Figure 8B). Rescure IKKα by overexpressing IKKα in IKKα–/– MEFs leads to
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decreasing of NUMB expression and upregulation of NICD expression accordingly
(Figure 8B).
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Fig 7 IKKα, but not IKKβ downregulates NUMB expression
(A) Hep3B and Huh-7 cells were treated with TNFα (20 ng/ml) for 24 h.
Endogenous NICD and NUMB expression levels were examined by western
blotting. α-Tubulin was used as loading control.
(B) Hep3B cells were transfected with IKKα and IKKβ. Endogenous NICD and
NUMB expression was analyzed by western blotting. α-Tubulin was used as
loading control.

vector

IKKα

NICD
NUMB
IKKα
IKKβ
α-TUBULIN
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IKKβ

Fig 8 Knocking down IKKα impaired TNFα-induced NOTCH1 activation and
increased NUMB expression
(A) Knockdown of IKKα or double knockdown of IKKα and NUMB by siRNA in
Hep3B cells. Nontargeting siRNA was used as control. After 24 h of TNFα
treatment, cell lysates (30 μg) were subjected to western blotting to detect
endogenous NICD and NUMB expression. α-Tubulin was used as loading control.
(B) Western blot analysis of endogenous NICD and NUMB expression in WT MEFs
and IKKα–/– MEFs with or without reconstituted IKKα. α-Tubulin was used as
loading control.
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CHAPTER 6 IKKα kinase activity is a key factor for TNFα induced NUMB
suppression and consequent NOTCH1 activation

IKKα is a well-known downstream kinase of TNFα signalling, the next question
naturally comes out “ does IKKα trigger NUMB/NOTCH1 signalling via its kinase
activites” Kinase-dead (KD)IKKα mutant, which does not have any kinase activites,
were introduced into hepatocyte cells. We found not similar to wide type IKKα,
kinase-dead (KD) IKKα mutant could not downregulate NUMB expression (Figure
9A), indicating that TNFα/IKKα induce NUMB downregulation and NOTCH1
activation via IKKα kinase activites. . In addition, RBP-Jk luciferase assay showed
that overexpression of NUMB could block TNFα-induced NOTCH1 activation
(Figure 9B). To answer does IKKα-induced NOTCH1 activation functionally affects
the NOTCH1, we detected transcriptional change of some NOTCH1 downstream
genes. RNA levels of c-Myc, p21, p27, Hes6, Hey1, and Hey2 were measured via
real-time PCR with IKKα or NUMB expression. The mRNA levels of NOTCH1
downstream targets enhanced with IKKα but were decreased in the presence of
NUMB (Figure 9C). Together, these results indicate that TNFα triggered IKKα
kinase activity could activate NOTCH1 through NUMB suppression.
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Fig 9 IKKα functionally effects NOTCH1 activities and suppression NUMB
(A) Hep3B cells were transfected with WT IKKα or KD IKKα. Endogenous NICD
and NUMB expression was analyzed by western blotting. α-Tubulin was used as
loading control.
(B) RBP-Jk Luc and NUMB were transfected into Hep3B cells for 48 h. After
transfection, Hep3B cells were treated with TNFα (20ng/ml) for 24 h. Cell lysates
were subjected to the luciferase reporter assay. NUMB expression was analyzed
by western blotting with 10 μg of total lysates. Error bars represent SD (n = 3). *
indicates statistical significance (P < 0.05).
(C) Hep3B cells were infected with retrovirus expressing IKKα or IKKα and NUMB.
RNA extracts were purified from the cell lysates and quantitated with real-time PCR.
The NOTCH1 target gene mRNA levels were normalized to the mRNA levels of
target genes in vector-infected cells. Error bars represent SD (n = 3). * indicates
statistical significance (P < 0.05).
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CHAPTER 7 NUMB was transcriptionally regulated by TNFα/IKKα via FOXA2

Since we know NUMB expression could be regulated by TNFα/IKKα, we
further investigate the underneath molecular mechanism. We first checked the
status NUMB mNRA using quantitative PCR (qPCR) after TNFα treatment in both
Huh-7 and Hep3B cells. We found that mRNA of NUMB is decreased with TNFα
treatment compared those without TNFα treatment (Figure 10A). Next, NUMB
promoter was analysis to investigate possible candidates of transcriptional
regulators on NUMB promoter activity. PROMO 8.3 program analysis results
revealed five types of hepatocyte nuclear factor (HNF) binding sites richly clustered
on the NUMB promoter (Figure 10B). HNFs are well known transcriptional factors
involving in a wide spectrum of cell process in multiple human cancers, we further
investigated whether and which HNFs associates with TNFα/IKKα mediated NUMB
transcription regulation. Only FOXA2 (HNF3β)-upregulated NUMB mRNA level
was reduced with IKKα occurrence, indicating that FOXA2-activated NUMB
transcription can be inhibited by IKKα (Figure 10C). Collectively, these results
indicate that FOXA2, as a transcriptional factor of NUMB promoter, will decrease its
transcriptional abilities on NUMB promoter with TNFα, therefore downregulate
NUMB expression and activation of NOTCH1.
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Fig 10 NUMB was transcriptionally regulated by TNFα/IKKα via FOXA2
(A) Hep3B and Huh-7 cells were treated with TNFα (20 ng/ml) for 24 h. NUMB
mRNA level was detected with qPCR. Error bars represent SD (n = 3). * indicates
statistical significance (P < 0.05).
(B) The TRANSFAC 7.0 and PROMO 8.3 programs were used to predict
transcriptional factors that bind to the NUMB promoter. Five HNFs were identified
from the prediction.
(C) Each of the five indicated HNFs was transfected alone or together with IKKα
into Hep3B cells. NUMB mRNA level was detected with real-time PCR. Error bars
represent SD (n = 3). * indicates statistical significance (P < 0.05).
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CHAPTER 8 IKKα Interacts with and phosphorylates FOXA2 in vitro

Based on previous findings, the next coming out question goes to how
FOXA2 activity was inhibited by IKKα. Since the kinase activity of IKKα involves in
NUMB suppression and NOTCH1 activation, we first tested the interaction between
IKKα and FOXA2 in vivo. Reciprocal co-immunoprecipitation showed that IKKα
physically associated with FOXA2 (Figure 11A). The same protocol were used to
detect the interaction between endogenous IKKα and FOXA2 using specific
antibodies against IKKα and FOXA2 (Figure 11B). In addition, In vitro GST or His
pull-down assays further supported only IKKα, but not

IKKβ, could binds with

FOXA2 (Figure11C). Based on the physical association between IKKα and FOXA2,
we examined whether IKKα could phosphorylate FOXA2. GST-FOXA2 was
phosphorylated by purified recombinant IKKα in in vitro kinase assay. (Figure 11D,
compare lanes 1 and 2). To further confirm and identified phosphorylation sites on
FOXA2 by IKKα, we analyzed the kinase assay samples by mass spectrometry
(MS) and found that FOXA2 was phosphorylated by IKKα at S107 and S111 (Figure
11E). Mutation of these two sites from serine to alanine abolished IKKα-mediated
FOXA2 phosphorylation (Figure11D, lane 5). Taken together, these data
demonstrate that IKKα interacts with and phosphorylates FOXA2 at S107/111 in
vitro.
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Fig 11 IKKα Interacts with and phosphorylates FOXA2 in vitro
(A) IKKα and FOXA2 were transfected into 293T cells and analyzed by reciprocal
co-immunoprecipitation and immunoblotting using indicated antibodies.
(B) Lysates of Hep3B cells were analyzed by reciprocal co-immunoprecipitation
and immunoblotting using indicated antibodies.
(C) In vitro transcribed FOXA2 proteins (labeled with S35) were incubated with
commercially available recombinant His-IKKβ and GST-IKKα and then pulled down
with His/GST beads. IVT: in vitro transcription and translation. S35 concentration in
cell lysates was determined by film exposure.
(D) FOXA2 phosphorylation was identified by in vitro kinase assay. GST-FOXA2
was pulled down by GST beads from Hep3B cells and incubated with commercially
available IKKα for 30 min.
(E) Mass spectrum of FOXA2 phosphorylation sites by IKKα using samples
(without isotope) from (D).
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CHAPTER 9 IKKα Interacts with and phosphorylates FOXA2 in vivo
Although we identified two phosphorylation sites on FOXA2 in vitro, we need to
further identified IKKα could phosphorylates FOXA2 on these two sites in vivo.
endogenous FOXA2 were isolated from TNFα treated Hep3B cells to perform MS
analysis. These two phosphorylation sites were included in other 12 phosphorylate
sites on FOXA2 with TNFα treatment (Figure 12A). For further investigation, we
synthesized peptide including 107/111 phosphorylation sites and injected to mouse
to raise specified mouse polyclonal antibodies against pFOXA2 at S107/111. The
western immunoblotting assay showed that the antibody recognized specifically
pFOXA2 (S107/111) phosphorylated by WT IKKα but not by KD IKKα (Figure 12B).
The pFOXA2 antibody also recognized phosphorylated WT FOXA2 but not the
double mutant with both serine residues mutated to alanine (FOXA2-SSAA), further
supporting its specificity (Figure 12C). In addition, the pFOXA2 (S107/111) antibody
detected pFOXA2 only in the presence of IKKα in an in vitro kinase assay (Figure
12D). Time course assays to study the effect of TNFα showed that levels of
pFOXA2 (S107/111) were high at 10–30 min and declined thereafter (Figure 12E),
consistent with the kinetics of TNFα-induced IKKα activation as measured by
degradation of IκBα.
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Fig 12 IKKα Interacts with and phosphorylates FOXA2 in vivo
(A)Hep3B cells were treated with TNFα for 24 h, and cell lysates were analyzed by
MS to identify in vivo FOXA2 phosphorylation sites.
(B) Hep3B cells were co-transfected with FOXA2 and WT IKKα or KD IKKα.
pFOXA2 expression was detected using an antibody specific to pFOXA2
(S107/111). Cell lysates (10 μg) wereloaded for western blotting.
(C) IKKα was co-transfected with WT FOXA2 or FOXA2-SSAA. pFOXA2
(S107/111) was detected using an antibody specific to pFOXA2 (S107/111). Total
FOXA2 expression and IKKα expression are also shown.
(D) Western blot analysis of pFOXA2 with an antibody specific to pFOXA2
(S107/111) using samples (without isotope) from (D). Total FOXA2 expression and
IKKα expression are also shown.
(E) Hep3B cells were treated with TNFα and harvested at 10, 30, 60, and 120 min
after treatment. Cell lysates (40 μg) were used for western blot analysis of pFOXA2
with an antibody specific to pFOXA2 (S107/111). Total FOXA2 expression and
IKKα expression are also shown.
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CHAPTER 10 IKKα phosphorylates FOXA2 in nucleus
Previous reports showed that response to TNFα, IKKα would translates from
cytoplasm to nucleus and regulate its downstream target transcriptionally or
translationally. To identify the subcellular location of FOXA2, IKKα before and after
TNFα treatment, we perform cell fraction to identify the expression level of both
proteins in different cell parts. We treated IKKβ–/– MEFs with TNFα and isolated the
nuclear and cytoplasmic fractions from the cells for immunoprecipitation by the
IKKα antibody. We found that stimulation of IKKβ–/– MEFs with TNFα increased
nuclear accumulation of IKKα, the amount of FOXA2 bound to IKKα, and
phosphorylation of FOXA2 (S107/111). However, we did not detect either pFOXA2
or FOXA2 expression in the cytoplasm after TNFα treatment, suggesting that TNFα
increased the nuclear accumulation of IKKα which phosphorylates FOXA2 in
nucleus. (Figure 13)
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Fig 13 IKKα phosphorylates FOXA2 in nucleus
IKKβ–/– MEFs were treated with TNFα for 45 min. Cell lysates were subjected to cell
fractionation. After immunoprecipitation by the IKKα antibody, the nuclear and
cytoplasmic fractions were subjected to western blot analysis with indicated
antibodies. Lamin and tubulin were used as cell fractionation controls.
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CHAPTER 11 FOXA2 Phosphorylation

by IKKα

Suppresses FOXA2

transactivation Activity
Since upon TNFα stimulation, IKKα phosphorylates FOXA2 and leads to
NUMB suppression, it is possible that FOXA2 lost its function as a transcriptional
factor after being phosphorylated by IKKα, therefore leads to the suppression of
NUMB and consequently NOTCH1 pathway enhancement. To test this hypothesis,
we constructed a plasmid containing FOXA2-responsive elements (FRE) to drive
the luciferase reporter, which could mimic FOXA2 downstream gene promoter
activites and monitor the FOXA2 transactivation activity in general. After we
introduced it to 293T cells, we found that WT IKKα could suppress FOXA2
transactivation activity, but the activity would not be affected by KD IKKα (Figure
14A). The similar results represents in luciferase reporter assay used a plasmid
containing. a 1kb key promoter of NUMB which drives luciferase reporter gene to
detect NUMB promoter activities with or without IKKα effects (Figure 14B).
To test whether IKKα suppression activities on FOXA2 comes from the two
specific phosphorylation sites on FOXA2 (S107/111), we double mutated the two
critical Serine amino acids to either Alanine or Glutamine, which mimic the
nonphosphorylated and phosphorylated state of FOXA2. The NUMB promoter
drived luciferase reporter assay showed that FOXA2-SSEE could not activate
NUMB promoter activities comparing to WT FOXA2, but the present of
FOXA2-SSAA has the similar transactivation activities to WT FOXA2. (Figure 14C)
In addition, Unlike WT FOXA2, FOXA2-SSEE and FOXA2-SSAA maintained their
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transactivation activities regardless the status of IKKα, suggesting that
phosphorylation of FOXA2 at S107/111 is the major factors to effect FOXA2
transactivation activity (Figures 14C and 14D). These results support that IKKα
decreased FOXA2 transactivation activity by phosphorylating FOXA2 at S107/111.
To detect whether the reduction transactivation activities of FOXA2 is the reason
for the suppression of NUMB expression with TNFα treatment, we examined the
NUMB mRNA level by transfecting various FOXA2 constructs expressing WT
FOXA2, FOXA2-SSAA, FOXA2-SSEE, or vector control into Hep3B cells. As
expected, FOXA2-SSAA, but not FOXA2-SSEE, enhanced NUMB mRNA level
(Figure

14E).

These

results

further

support

the

phosphorylation inhibits FOXA2 transactivation activity.
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notion

that

S107/111

Fig 14 FOXA2 Phosphorylation by IKKα Suppresses FOXA2 transactivation
activity
(A) Six repeated consensus binding sites of FOXA2 were constructed into
Luc-driven reporter (FRE-Luc). NUMB promoter luciferase reporter and FOXA2 in
the presence of different doses of WT IKKα or KD IKKα were transfected into 293T
cells for 48 h. Cell lysates were subjected to luciferase reporter assays after
transfection. The luciferase activities were normalized to mock cells with NUMB
promoter luciferase reporter. Error bars represent SD (n = 3). * indicates statistical
significance (P < 0.05).
(B) NUMB promoter luciferase reporter and FOXA2 in the presence of different
doses of WT IKKα or KD IKKα were transfected into 293T cells for 48 h. Cell
lysates were subjected to luciferase reporter assays after transfection. Expression
levels of WT IKKα, KD IKKα, and FOXA2 were analyzed by western blotting. Error
bars represent SD (n = 3). * indicates statistical significance (P < 0.05).
(C) Co-transfection of NUMB-promoter Luc and WT FOXA2, FOXA2-SSAA, or
FOXA2-SSEE plus the indicated Flag-tagged IKKα in 293T cells for 48 h. Lysates
of 293T cells were subjected to luciferase assays. Error bars represent SD (n = 3).
* indicates statistical significance (P < 0.05). Expression levels of IKKα, WT FOXA2,
and FOXA2 mutants were detected by western blot analysis.
(D) Co-transfection of FRE-Luc and WT FOXA2, FOXA2-SSAA, or FOXA2-SSEE
plus the indicated Flag-tagged IKKα in 293T cells for 48 h. Lysates of 293T were
subjected to luciferase assays. Error bars represent SD (n = 5). * indicates
statistical significance (P < 0.05).
(E) Hep3B cells were infected with retrovirus expressing FOXA2-SSAA or
FOXA2-SSEE. RNA extracts from the cells were isolated and subjected to
real-time RT-PCR for NUMB mRNA expression. Error bars represent SD (n = 3). *
indicates statistical significance (P < 0.05).
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CHAPTER 12 FOXA2 Phosphorylation by IKKα decreases FOXA2 DNA
binding activities

Since we know that FOXA2 transactivation activities decrease after being
phosphorylated by IKKα, the further question naturally comes to the underneath
molecular mechanism involving in the inhibition activities. The DNA binding ability
is a crucial factor to influent transactivation activities of transcriptional factors, we
first examined the difference in the binding ability of FOXA2 to the NUMB promoter
before and after TNFα treatment. We performed a chromatin immunoprecipitation
(ChIP) assay using primers spanning the putative FOXA2 binding sites (see primer
sequences in the Experimental Procedures section) in the NUMB promoter from
Hep3B cell lysates with or without TNFα treatment. We found that binding of
FOXA2 to the NUMB promoter was decreased by TNFα (Figure 15A, to left of
arrow). In addition, we compared the binding ability of WT FOXA2, FOXA2-SSAA,
and FOXA2-SSEE to the NUMB promoter by ChIP and found that WT FOXA2 and
FOXA2-SSAA, but not FOXA2-SSEE, bound to the NUMB promoter (Figure 15B),
suggesting

that

FOXA2

phosphorylation

by

IKKα

suppressed

FOXA2

transactivation activity on NUMB by decreasing FOXA2 accessibility to its promoter.
We further tested the function of FOXA2-SSAA and FOXA2-SSEE in
FOXA2-knockdown Hep3B cells. The western immunoblotting assay showed that
both WT FOXA2 and FOXA2-SSAA stimulated NUMB protein level (Figure 15C).
WT FOXA2 expression could suppressed NUMB enhancement with TNFα
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stimulation, (Figure 15C, compare lanes 2 and 6) but FOXA2-SSAA has no effect
on FOXA2 –induced NUMB enhancement (compare lanes 3 and 7). Moreover,
FOXA2-SSEE has no response to TNFα treatment (lane 8), suggesting that
phosphorylation of FOXA2 on S107/111 is the major reason for suppression the
FOXA2 associated NUMB expression. The results of monitoring NOTCH1 activities
by RBP-Jk luciferase reporter assay showed the FOXA2-associated NOTCH1
suppression could be released by mimic phosphorylated FOXA2-SSEE (Figure
15D). Collectively, our results indicate that S107/111 phosphorylation of FOXA2 by
IKKα limit the FOXA2 DNA binding ability, leads to less FOXA2 transactivation
activities on NUMB promoter, therefore suppress NUMB promoter activities, NUMB
mRNA level and protein expression, and triggers NOTCH1 signalling as a results.
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Fig 15 FOXA2 Phosphorylation by IKKα decreases FOXA2 DNA binding
activities
(A) Hep3B cells were treated with TNFα for 24 h, and cell lysates were harvested
and subjected to primary ChIP assay using the FOXA2 antibody. The purified DNA
from the ChIP assay was subjected to real-time PCR using NUMB primers (to left
of arrow). Error bars represent SD (n = 3). * indicates statistical significance (P <
0.05).
(B) Endogenous FOXA2 in Hep3B cells was knocked down by shRNA against the
5′-UTR. After shRNA knockdown of FOXA2, we transfected WT FOXA2,
FOXA2-SSAA, or FOXA2-SSEE into FOXA2–/– Hep3B cells, followed by TNFα
treatment for 24 h. Cell lysates were analyzed by western blotting using indicated
antibodies.
(C) RBP-Jk Luc and WT FOXA2, FOXA2-SSAA, or FOXA2-SSEE were
co-transfected into Hep3B cells for 24 h, followed by TNFα treatment for 24 h. Cell
lysates were analyzed by luciferase reporter assay. Error bars represent SD (n = 3).
* indicates statistical significance (P < 0.05).
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CHAPTER
13
FOXA2
Phosphorylation
by
FOXA2-Mediated Repression of Cell Growth In Vitro

IKKα

De-Represses

Previous reports showed that NUMB and NOTCH1 pathway involves in cell
proliferation in many type of cancers, we next to test if IKKα-induced FOXA2
phosphorylation associates with cell proliferation and growth in HCC cells. We
examined the function of non-phosphorylation FOXA2, phosphorylation FOXA2
and

WT

FOXA2

in

cell

growth

by

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. We
found that both FOXA2-SSAA and WT FOXA2 would inhibit cell growth compared
to control or FOXA2-SSEE cells (Figure 16A). In addition, WT IKKα, but not KD
IKKα, showed the ability to recovered Hep3B cells growth suppression from WT
FOXA2 expression, presumably as a result of phosphorylation of WT FOXA2 by
IKKα, which leads to loss function of FOXA2 in terms of inhibition of cell growth.
(Figure 16D). Knocking down NUMB reversed the cell growth inhibition by WT
FOXA2 and FOXA2-SSAA, supporting our proposed suppressive role of NUMB in
the TNFα/IKKα pathway (Figure 16B). To verify that NOTCH1 activation is the main
reason leading to cell growth in this TNFα/IKKα triggered pathway, we knocked
down NOTCH1 in Hep3B cells to monitor cell growth in MTT assay. The results
showed that Hep3B cell growth was inhibited after NOTCH1 knockingdown
regardless of FOXA2 phosphorylation status, demonstrating that NOTCH1
signaling activation was the major reason for the TNFα/IKKα induced cell growth
(Figure 16C). We also use two NOTCH1 pathway inhibitors, LY-411575 and
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γ-secretase inhibitor (GSI) to block NOTCH1 pathway in different liver cancer cell
lines to detect the influence on cell growth by counting cell numbers. The results
showed that after NOTCH1 inhibitors treatment, the cell growth of all liver cancer
cell lines decreased, further supporting that NOTCH1 activation plays an important
role in liver cancer cell growth (Figure 16E). Consistent with MTT results,
FOXA2-SSAA inhibited cell colony formation in an anchorage-independent growth
assay (Figure 19F upper). Without NUMB expression would significantly increase
colony formation no matter what the status of FOXA2. (Figure 16F bottom). When
NOTCH1 was knocked down, colony formation was diminished which is consistent
to cell growth (Figure 16G bottom).
To verify the status of DNA synthesis under these conditions, we also
performed a bromodeoxyuridine (BrdU) incorporation assay. We found the similar
results to MTT assay and anchorage-independent growth assay. (Fig 16 H, I)
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Figure 16 FOXA2 Blocks IKKα-Induced Cell Proliferation and Tumor Growth
In Vitro
(A, B, and C). Hep3B cells were infected with retrovirus expressing WT FOXA2,
FOXA2-SSAA, or FOXA2-SSEE in the presence of (A) control shRNA, (B) NUMB
shRNA, or (C) NOTCH1 shRNA. Cells (2.5 × 103) were plated in 96-well plates, and
cell growth was determined by MTT assay each day for 4 days.
(D) WT IKKα or KD IKKα was co-transfected with GFP-tagged WT FOXA2,
FOXA2-SSAA, or FOXA2-SSEE into Hep3B cells. After 48 h, GFP-positive cells
were sorted by flow cytometry. Sorted cells were seeded in 96-well plates at
5000/well and subjected to MTT assay. Error bars represent SD (n = 3). * indicates
statistical significance (P < 0.05).
(E) Huh-7, HepG2, Hep3B, PLC/PRF/5, HA22T/VGH, HA59T/VGH, Mahlavu,
Tong/HCC, and SK-Hep-1 cells were serum-starved for 24 h and then treated with
LY-411575 (250 μM), GSI (10 μM), or DMSO for 48 h. After treatment, cells were
counted with a Beckman Coulter cell counter. Error bars represent SD (n = 5).
(F.and G). Anchorage-independent growth assay of Hep3B cells infected with
retrovirus expressing WT FOXA2, FOXA2-SSAA, or FOXA2-SSEE in the presence
of (F) NUMB shRNA or (G) NOTCH1 shRNA, compared with control shRNA.
Colony numbers (mean ± SD) in week 3 are shown (n = 6). * indicates statistical
significance (P < 0.05, Student’s t test). Representative images from the
anchorage-independent growth assay are shown below.
(H) KD IKKα inhibited Hep3B cell proliferation. WT FOXA2, FOXA2-SSAA, or
FOXA2-SSEE and WT IKKα or KD IKKα were co-transfected into Hep3B cells.
After 48 h, cells were subjected to BrdU assay and analyzed by flow cytometry.
(I) Hep3B cells were infected with retrovirus expressing WT FOXA2, FOXA2-SSAA,
or FOXA2-SSEE either without (top) or with (bottom) NUMB shRNA. Infected cells
were subjected to BrdU assay and analyzed by flow cytometry.
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FOXA2-Mediated Repression of Cell Growth In Vivo
The tumor promotion functions of IKKα-induced FOXA2 phosphorylation were
further confirmed in mouse model. We injected Hep3B cells into three groups of
nude mice using an orthotopic liver cancer animal model (Xiong, et al., 2010). We
monitored the tumor volume (TV) of these mice for 6 weeks and analyzed tumor
tissue samples by western blotting. To determine the role of IKKα in liver tumor
growth, we injected the first group of mice with Hep3B cells infected with retrovirus
expressing shRNA against IKKα. TV was much smaller in the mice harboring
tumors (after transplantation) than in the control group, validating the role of IKKα in
liver tumor growth (Figure 17A). Western blot analysis of these tumor tissue
samples detected TNFα in tumors along with decreased FOXA2 phosphorylation,
enhanced NUMB expression, and attenuated NICD expression (Figure 71B). The
second group of mice was injected with cells infected with retrovirus expressing WT
or mutant FOXA2, and transplantation was performed essentially as described for
the first group. We found that WT FOXA2 and FOXA2-SSAA both inhibited tumor
growth, whereas FOXA2-SSEE had no effect (Figure 17C, top). In addition, NUMB
expression was increased with a decrease in NICD expression in the WT FOXA2
and FOXA2-SSAA tumors (Figure 17C, bottom). Together, these results suggest
that FOXA2-SSAA functions in a dominant manner to inhibit tumor growth and
support the importance

of

IKKα

in

development.
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promoting

FOXA2-associated

HCC

Previously, we showed that knockdown of NUMB increased cell growth rate
and colony formation regardless of FOXA phosphorylation status. To demonstrate
the role of NUMB in TNFα/IKKα-induced tumor growth in vivo, we knocked down
NUMB by shRNA in Hep3B cells infected with retrovirus expressing WT FOXA2
and its mutants. Mice that received transplanted tumors harboring these
NUMB-knockdown cells continued to show tumor growth even in the presence of
FOXA2 and FOXA2-SSAA, which was probably due to restored NICD expression
and is consistent with results from the in vitro assays (Figure 17D, bottom).
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Figure 17. FOXA2 Blocks IKKα-Induced Cell Proliferation and Tumor Growth
In Vivo
(A) Hep3B cells were infected with retrovirus expressing control or IKKα shRNA.
Mice were injected subcutaneously with 1 × 106 cells. Error bars represent SD (n =
5). Please see the Experimental Procedures section for more detailed information.
(B) Tumor tissues from mice that received transplants were analyzed 10 days after
transplantation and subjected to western blot analysis for indicated antibodies.
Right: Expression levels of pFOXA2, NUMB, and NOTCH1 quantified with ImageJ
software.
(C) Hep3B cells were infected with retrovirus expressing WT FOXA2,
FOXA2-SSAA, or FOXA2-SSEE in the presence of (top) control shRNA or (bottom)
NUMB shRNA. Error bars represent SD (n = 5). Please see the Experimental
Procedures section for more detailed information.
(D) Tumor issues from (C) were harvested 10 days after transplantation and
subjected to western blot analysis for NICD, FOXA2, and NUMB. α-Tubulin was
included as control.
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CHAPTER 15 FOXA2 Phosphorylation by IKKα play roles in liver cancer

In addition, to further examine the aforementioned conclusion that FOXA2
phosphorylation by TNFα-induced IKKα plays a critical role in liver cancer, we
examined the expression of IKKα, pFOXA2 (S107/111), and NICD in 30 freshly
prepared human primary HCC tumor specimens and paired normal liver tissues by
immunoblotting. We found that IKKα, pFOXA2 (S107/111), and NICD expression
levels were significantly higher in tumor specimens than in the corresponding
normal liver tissues (P < 0.05) (Figures 18A, 18B). In addition, pFOXA2 expression
was positively correlated with expression of IKKα and NICD. These results
strengthen the notion that IKKα regulates FOXA2 and activates NICD through
phosphorylation at S107/111 and the physiological implication of pFOXA2 in
IKKα-induced tumorigenesis (18C, 18D). Taken together, analyses of these clinical
HCC tumor specimens support that FOXA2 phosphorylation by IKKα might be
associated with HCC tumorigenesis.
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Fig 18 FOXA2 Phosphorylation by IKKα play roles in liver cancer
(A, B) Comparison of pFOXA2 (S107/111), IKKα, and NICD expression in tumors
and their adjacent normal tissues. Protein expression was examined by
immunoblotting 30 pairs (tumor and normal) of liver tissue samples and quantified
with ImageJ software. Right: Four representative pairs (N, normal; T, tumor).
Protein expression levels in tumor samples were normalized to those in paired
normal tissues. Protein expression levels higher (or lower) than those in normal
tissues were defined as “high” (or “low”).(P < 0.01, Pearson’s chi-square test.)
(C, D) Correlation analysis of pFOXA2 and IKKα/NICD expression levels in tumors
(R2 > 0.5, Spearman’s rank correlation test).
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CHAPTER 16 Summary & Discussion
Summary
Here, we identified an axis in TNFα pathway involving activation of NOTCH1
signaling through suppression of FOXA2 transactivation activity by IKKα, leading to
disruption of NUMB expression, which promotes NOTCH1-induced liver cell
proliferation and growth. In our proposed model, TNFα-activated IKKα interacts
with and phosphorylates FOXA2. We identified two IKKα-mediated FOXA2
phosphorylation sites, Ser107 and Ser111. Phosphorylation at these two sites
decreased FOXA2 transactivaction activities, reduced the expression of a FOXA2
downstream target gene, NUMB, and subsequently, increased tumor growth.
Analysis of HCC patient tumor tissue samples suggests that phosphorylation of
FOXA2 on Ser 107/111 residues could be a new marker for detecting
inflammation-induced liver cancer.
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Fig 19

Model of TNFα induced FOXA2/NOTCH1 pathway
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Discussion
Inflammation, TNFα and Liver Cancer:
It is not surprise to see inflammation has a tight relationship to human cancers. In
our daily life, food factors, stress, environmental pollution, bacteria and viruses
could increase expression of chemokines and cytokines, including TNFα. The
enhancement of chemokines and cytokines will further induce acute inflammation
and chronic inflammation. Almost all acute inflammations are responded quickly by
human innate immunity system. Chronic inflammation will turns to increase the
potential possibilities of cancer in certain organs.
As one of the most important cytokines, TNFα has a large amount of activities in
cell to cell communications and inflammation-associated human cancers.
Dysregulation of TNFα signaling pathway contributes to the development of human
cancers due to enhanced IKK complex activity and regulate NF-κB downstream
oncogenic target genes including cytokines, chemokines, enzymes, survival genes
and some of angiogenesis factors. There are several mouse model were set up
which could provide more evidence for the role of TNFα in cancers, especially in
liver cancer.
The most direct evidence to show the tumor-promoting role of TNFα was
similarly investigated in models of hepatic carcinogenesis. TNFRI-/- mice displayed
reduced oval cell (hepatic stem cell) proliferation during the pre-neoplastic phase of
liver carcinogenesis, correlating with fewer tumours than wild-type mice
In addition, one of the most famous liver cancer mouse models is
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DEN-induced hepatocarcinogenesis model Dr. Michael Karin, who has previously
set up the DEN system, indicated in some of his papers that the DEN-induced
hepatocarcinogenesis model is “TNF-independent”. Data from these papers
showed that upon DEN induction, the tumor multiplicity and maximum size of the
lack of TNFR1 (TNFα receptor) mouse has no significant difference to those of wild
type mouse, indicating TNFα signaling is not required for DEN-induced
hepatocarcinogenesis.
Another model related to TNFα/IKK roles in liver cancer is the Mdr2-KO mouse
model, It is an inflammation-associated model of HCC, which is directly linked to
NF-κB. The Mdr2-KO mouse system was engineered Dr. Yinon Ben-Neriah, who
showed that NF-κB functions as a tumor promoter in inflammation-associated liver
cancer by anti-TNFα treatment or ectopic expression of an IκB-super-repressor
transgene (Pikarsky, 2004). To the best of our knowledge, an independent role of
IKK complex unit in Mdr2-KO mouse has not been reported yet. It would be of
interest to test our findings in this Mdr2-KO mouse system.

NOTCH1 and Cancers
We demonstrate that TNFα also stimulates the NOTCH1 pathway in liver cancer
cell lines. Previous studies have reported that NOTCH1 has two different roles, one
that promotes and the other that suppresses tumorigenesis. Which of the two roles
is going to be dominant is dependent on the cellular context and the crosstalk with
other signal-transduction pathways.
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Although NOTCH1 has been shown to play a role as an oncogene in mainly
in leukemia and breast cancer, one report demonstrated inhibition of HCC tumor
growth through NOTCH1 signaling by induction of cell cycle arrest and apoptosis114.
Several groups that analyzed clinical samples of human HCC also indicate a
positive role of NOTCH1 in liver cancer115-117. More recently, Ning et al. specifically
showed downregulation of NOTCH1 signaling inhibited tumor growth in human
HCC in both cell lines and mouse model118. These studies are in line with our
findings that NOTCH1 is activated by TNFα through deregulation of FOXA2
transactivity to promote cell proliferation and growth.
NOTCH1 signaling plays an oncogenic role in a majority of solid tumors, and
thus, NOTCH1 inhibition may represent a viable treatment for cancer. So far, the
best-developed tool for NOTCH1 signaling inhibition is a small molecule inhibitor of
γ-secretase. In clinical trial, γ-secretase inhibitor for cancer therapy faced
challenges for its high cytotoxicity and non-specific targeting48.

FOXA2 proteins and Cancers
Some FOX subfamilies such as FOXO, FOXM, FOXP, FOXC, and FOXA
have been linked to tumorigenesis and the progression of certain cancers. For
instance, the loss of FOXA2 activity may increase EMT in both lung cancer and
pancreatic cancer119-120. IN addition, FOXA2 proteins are found to be a key
regulator in lung inflammation38. In our model, we showed that a new FOX family
member plays important role in inflammation-induced liver cancer. FOXA2 is a
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transcriptional factor that binds to the NUMB promoter in both genome-wide screen
and software analysis. FOXA2 recently We showed that phosporylation of FOXA2
by IKKα resulted in the loss of FOXA2 transactivation activity and decreased its
binding capacity to the NUMB promoters, and therefore, activates NOTCH1
pathway. The crystal structure of FOXA2 DNA binding domain was published in
1993; however, the crystal structure of full-length of FOXA2 is not yet available.
The phosphorylation sites that we identified (S109/111) are located in domain
between TAD and WHD. The results from the CHIP assay suggested that
phosphorylation on Ser 109/111 decreased the ability of FOXA2 to associate with
the NUMB promoter. In addition, FOXA2 is known to associate with some
promoter-associated factors such as TBP (TATA Box binding protein), HNF6, and
the other two FOXA family members, FOXA1 and FOXA3. At this moment, it is not
clear and would require further investigation to determine how phosphorylation of
Ser 109/111 affects DNA-binding activity and/or its interaction with other
transcription factors.
In summary, the identification of FOXA2 as a downstream substrate of IKKα
links the TNFα and NOTCH1 signaling pathways and provides an important new
starting point for uncovering the molecular basis of TNFα-mediated human tumor
growth and identifying potential targets for cancer therapy. Inhibition of FOXA2
phosphorylation or activation of NUMB could have important clinical implications for
the treatment or prevention of cancer.
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FUTURE DIRECTION
We previously found that phosphorylation of FOXA2 by IKKα induces tumorigenesis
through activating NOTCH pathway in a cell culture system and an orthotopic
mouse model, but the in vivo role of these phosphorylations in tumorigenesis is still
nebulous. In recent years, the use of knock-in technology to clarify the role of
phosphorylation of specific kinase targets in vivo has emerged as a valuable tool for
assessing the organism-wide importance of these signaling events49-51. Thus, we
will apply this strategy to engineer two phosphorylation mutants in the FoxA2
genetic locus (FoxA22A/2A and FoxA22E/2E knock-in alleles) to clarify the importance
of IKKα/FoxA2 signaling pathway in tumor progression.

Aim 1: Generate and characterize FoxA22A/2A and FoxA22E/2E knock-in mice.
Rationale: We previously found that phosphorylation of FOXA2 by IKKα induces
tumorigenesis through activating NOTCH pathway in a cell culture system and an
orthotopic mouse model

[43]

, but the in vivo role of these phosphorylations in

metabolism and tumorigenesis is still nebulous. In recent years, the use of knock-in
technology to clarify the role of phosphorylation of specific kinase targets in vivo has
emerged as a valuable tool for assessing the organism-wide importance of these
signaling events[21-23]. In this aim, we will apply this strategy to FoxA2 and will
engineer two mutants from the FoxA2 genomic locus (FoxA22A/2A and FoxA22E/2E
knock-in alleles) to clarify the importance of IKKα/FoxA2 signaling pathway in tumor
progression.
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Experimental design
a. Mouse embryonic stem cell targeting. The knock-in targeting construct
contains FoxA2 exons 1-3 and the neomycin selection cassette. The approach is
outlined in Figure 2 and described briefly here. The targeting construct will be
amenable to site-directed mutagenesis of the IKKα phosphorylation sites for Ser107
and Ser111, which will be mutated to encode alanin (A) or glutamic acid (E), and for
the insertion of a 2-kb floxed neomycin-resistance (Neo) cassette which allows
selection in both bacteria(on kanamycin) and in embryonic stem(ES) cells (on
neomycin/G418), into a unique XhoI site. The targeting construct will be provided to
The University of Texas M. D. Anderson Cancer Center Genetically Engineered
Mouse Facility (a core institutional resource) for ES cell targeting and neomycin
selection. We will screen Neo-positive clones for proper integration of the Neo
cassette and the two point mutations by Southern blot analysis with 5’ and 3’ probes
directed to the FoxA2 transgene in transgenic progenies. To remove the floxed Neo
cassette, FoxA2+/2A or FoxA2+/2D ES cells will be transfected with pMC-CrePuro,
which encodes for Streptomyces alboniger puromycin-N-acetyl-transferase and Cre
recombinase, and selected in medium containing puromycin. Selected clones will
be picked up and subjected to polymerase chain reaction (PCR) analysis using
primers

P1

(5’-CAAAACAAAACCAACTAACC-3’)

and

P2

(5’-GTAATTCTTTCCTGTCCCTG-3’). These primers result in a 324-bp product from
the wild-type allele and a 413-bp product from the targeted allele after the neomycin
cassette has been excised (Figure 20). After several independent strains of
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transgenic mice expressing either FoxA2-2A or FoxA2-2D have been generated, we
will choose two independent lines for our further studies.
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Fig 20 A diagram of knock-in strategy of the FoxA22A/2A and FoxA22E/2E allele

b. Generation of chimeric and FoxA22A/2A and FoxA22E/2E mice. Heterozygous
knock-in FoxA2+/2A and FoxA2+/2D ES cell clones will be microinjected into C57BL/6J
blastocysts, which will be then re-implanted into recipient female mice with the
assistance of the M. D. Anderson Cancer Center Genetically Engineered Mouse
Facility. Chimeric mice with a high degree of ES-cell contribution will be identified by
coat color and then crossed to 129/SvJae mice. This allows germline transmission
of the knock-in allele to be identified by the grey coat of the resulting pups. Multiple
chimeric offspring will be obtained and bred with wild-type C57BL/6J mice to
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produce F1 animals. Genotyping of FoxA2+/2A and FoxA2+/2D mice will be carried out
by PCR of genomic DNA isolated from tails or embryonic membranes. Primers P1
and P2, originally used to screen cells for the excision of the neomycin cassette, will
be used to genotype the mice. Homozygous knock-in FoxA22A/2A and FoxA22E/2E
mice will be generated by crossing FoxA2+/2A mice with FoxA2+/2A mice and
FoxA2+/2D mice with FoxA2+/2D mice, and the resulting pups will be genotyped by
PCR.

c. Phenotypic analyses of FoxA22A/2A and FoxA22E/2E mice. Once a knock-in line
is established, we will first assess any developmental defects in the FoxA22A/2A and
FoxA22E/2E mice by assessing the genotypes of offspring from the various crosses. If
embryonic lethality is observed for either of these genotypes, we will determine the
developmental stage at which the mice die and assess the defects leading to
mortality. Viability of FoxA22A/2A and FoxA22E/2E mice will show that this mutant
FoxA2 allele is functional in vivo, as FoxA2-/- death at E10-11. If no lethality is
observed for either FoxA22A/2A or FoxA22E/2E knock-in mice, we will use FoxA22A/2A
and FoxA22E/2E knock-in mice for further phenotypic characterization in which
cohorts of mice (20 of each genotype, 10 males and 10 females) will be killed at 6
and 12 months of age and sent to the M. D. Anderson Department of Veterinary
Medicine and Surgery for full necropsy. Necropsy analysis will include examination
and sectioning of brain, intestines, heart, lungs, thymus, kidneys, spleen, skeletal
muscle and liver, and organs will be cut into dorsoventral sections for histologic
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examination by standard H&E staining. We will also keep a cohort of FoxA22A/2A and
FoxA22E/2E littermates (20 of each genotype, 10 males and 10 females) for survival
and longevity studies.

Expected outcomes: Our previous in vitro study demonstrated that FoxA2 mutants
lacking IKKα phosphorylation sites can dominantly impair FoxA2 downstream target
gene activation. Because FoxA2 target genes are essential for early development in
mammals, it is possible that both FoxA22A/2A and FoxA22E/2E mice will exhibit early
developmental defects and embryonic lethality. It remains to be seen if this kind of
regulation for FoxA2 is critical during mammalian development. If embryonic
lethality is seen for either FoxA22A/2A or FoxA22E/2E mice, we will characterize the
cause of death in detail. Otherwise, we expect that heterozygous FoxA22E/2E mice
will develop polyps or intestinal lesions due to suppressed FOXA2 activity. A mild
inflammation which is associated with tumors may occur.

Possible experimental problems and alternative approaches: FoxA2 tumor
related function may affect tumor origination or tumor development or both. If
phosphorylation of FoxA2 by IKKα promoting but not initiating the tumor
development, we may not see tumor in previous mouse model. If it is the case, we
will alter to cross Apc716/+ mice (a mouse model of liver tumorigenesis) with our
knock-in mouse to see if FoxA22A/2A inhibit and FoxA22E/2E activate tumor
progression in Apc716/+ mice.
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Aim 2: Investigate FOXA2 downstream target gene inactivation, cell
proliferation and tumor development in FoxA22A/2A and FoxA22E/2E knock-in
mice.
Rationale: Because the TNFα/IKKα signaling pathway, which regulates FOXA2
downstream target genes inactivation through the inhibition of FOXA2 and
culminates in cell growth, has been studied only in vitro

[43]

, it remains unclear

whether this pathway affects FOXA2 downstream target gene inactivation, cell
metabolism, cell proliferation and tumor development in vivo. Thus, we propose to
determine whether FoxA22E/2E mice (in which FOXA2 is inactivated) show abnormal
target gene activation, metabolism disorder, cell proliferation, and tumor
development relative to wild-type mice or FoxA22A/2A mice (in which FOXA2 is
constitutively activated).

Experimental design: Different organs (including brain, intestine, heart, lungs,
thymus, kidneys, spleen, skeletal muscle and liver) of FoxA2+/+, FoxA22A/2A and
FoxA22E/2E mice will be dissected for assessment of typical FOXA2 downstream
target genes and NOTCH pathway marker (like c-myc, hes-1) by immunostaining.
The offspring of 20 litters (a target of at least 90 mice in total) will also be analyzed
for tumor development. Briefly, a cohort of FoxA22A/2A and FoxA22E/2E littermates (20
of each genotype, 10 males and 10 females) will be killed at 12 and 18 months of
age and sent to the M. D. Anderson Department of Veterinary Medicine and Surgery
for full necropsy and tumor examination.
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Expected outcomes: We expect to see that organs from FoxA22E/2E mice (with
inactivated FoxA2) will show higher expression of NOTCH pathway marker, like
Hes-1, Hey-6, c-Myc and less expression in FOXA2 target genes, like Numb, Gcg,
than FoxA2+/+ or FoxA22A/2A mice. Moreover, we may find that FoxA22E/2E mice have
a greater potential to develop various types of colorectal cancers compared with the
FoxA2+/+ and FoxA22A/2A mice. If using combination model of FoxA22E/2E×Apc716/+,
we expect to see the tumor growth in FoxA22E/2E×Apc716/+ mice will be larger than
that in Apc716/+ parental mice.
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